salicylates and Nail-Diseases

Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antimalarials; Azathioprine; Cushing Syndrome; Cyclophosphamide; Drug Eruptions; Gold; Humans; Lichen Planus; Nail Diseases; Pemphigus; Penicillamine; Pigmentation Disorders; Pruritus; Purpura; Salicylates; Skin Neoplasms; Urticaria

This double-blind randomized study was designed to compare the efficacy and safety of calcipotriol ointment (50 microg/g) with betamethasone dipropionate (64 mg/g) and salicylic acid (0.03 g/g) ointment in the treatment of nail bed psoriasis. Fifty-eight patients applied the given drug to the affected nails twice a day for 3-5 months, depending on clinical response. Efficacy was assessed monthly on the basis of nail thickness, measured in millimetres. Photographs of the treated nails were taken at baseline, and after 3 and 5 months. Tolerability was assessed at 3 and 5 months. In patients with fingernail psoriasis, after 3 months of treatment subungual hyperkeratosis was reduced from 2.3 +/- 0.1 mm (mean +/- SEM) to 1.5 +/- 0.1 mm (-26.5%) in the calcipotriol group and from 2.3 +/- 0.1 mm to 1.6 +/- 0.1 mm (-30.4%) in the betamethasone dipropionate and salicylic acid group [not significant (NS) between treatments, analysis of variance (ANOVA)]. After 5 months, responders showed a 49.2% reduction in hyperkeratosis in the calcipotriol group (from 2.8 +/- 0.1 mm to 1.4 +/- 0.2 mm) and 51.7% (from 2.1 +/- 0.1 mm to 1.0 +/- 0.1 mm) in the betamethasone dipropionate and salicylic acid group (P < 0.001 from baseline, NS between treatments, ANOVA). In patients with toenail psoriasis, after 3 months of treatment there was an overall reduction in hyperkeratosis from 2.6 +/- 0.1 mm to 2.1 +/- 0.1 mm (-20.1%) in the calcipotriol group and from 3.0 +/- 0.1 mm to 2.3 +/- 0.1 mm (-22. 9%) in the betamethasone dipropionate and salicylic acid group (P < 0.001 from baseline, NS between treatments, ANOVA). By the end of the fifth month there was a 40.7% reduction in hyperkeratosis in the calcipotriol group (from 2.1 +/- 0.1 mm to 1.2 +/- 0.1 mm) and 51.9% in the betamethasone dipropionate and salicylic acid group (from 2.7 +/- 0.1 mm to 1.3 +/- 0.1 mm; P < 0.0001 from baseline, NS between treatments, ANOVA). The results of the study show that calcipotriol is as effective as a combination of a topical steroid with salicylic acid in the treatment of nail psoriasis and represents a safe alternative in the topical treatment of nail psoriasis.

Topics: Adult; Aged; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Dermatologic Agents; Double-Blind Method; Female; Humans; Male; Middle Aged; Nail Diseases; Ointments; Psoriasis; Salicylates

Topics: Anti-Inflammatory Agents, Non-Steroidal; Bone Neoplasms; Diagnosis, Differential; Female; Foot Dermatoses; Humans; Nail Diseases; Nails; Onychomycosis; Osteoma, Osteoid; Salicylates; Toes; Young Adult

The authors report a case of a patient with pachyonychia congenita syndrome, a rare genodermatosis inherited as an autosomal dominant trait, who also had otological lesions beyond the other classic signs and symptoms of the syndrome. Many kinds of treatment have already been proposed, but all failed to show satisfactory results. A new, cheap and easy-to-use treatment was developed in this study, using keratoplastics interpolated with humectant lotion for 90 days. The results after three years of follow-up are still thoroughly satisfactory.

Topics: Adult; Drug Therapy, Combination; Ear, External; Emollients; Humans; Keratolytic Agents; Keratosis; Male; Nail Diseases; Propylene Glycol; Propylene Glycols; Salicylates; Salicylic Acid; Skin; Syndrome

Topics: Administration, Topical; Humans; Nail Diseases; Ointments; Salicylates; Salicylic Acid

Topics: Administration, Topical; Adult; Aged; Dichloroacetic Acid; Female; Foot Dermatoses; Hand Dermatoses; Humans; Male; Middle Aged; Nail Diseases; Ointments; Onychomycosis; Salicylates; Sulfur

Following the initial report by Farber and South on nonsurgical nail avulsion with urea ointment and their emphasis that the therapy was not helpful in treating nondystrophic nails, we utilized a similar therapy to treat a sixty-seven year old patient who had severe arteriosclerotic cardiovascular disease and relatively nondystrophic but symptomatic large toenail disease. Because their formulation was ineffective on nondystrophic nails, a formulation with an additive, 20 percent urea and 10 percent salicylic acid preparation was used. After a period of two weeks of occlusive paplication, painless nonsurgical avulsion was achieved. Moderate maceration of surrounding skin was temporary and relatively asymptomatic.

Topics: Aged; Drug Combinations; Female; Follow-Up Studies; Humans; Nail Diseases; Nails; Ointments; Salicylates; Urea